CLIN CANCER RES:Vanucizumab单药治疗晚期实体肿瘤

2018-04-16 MedSci MedSci原创

Vanucizumab是一种尚处于研究阶段的抗血管生产药物,靶向VEGF-A和Ang-2.CLIN CANCER RES近期发表了一篇文章,报道了Vanucizumab治疗晚期实体肿瘤的安全性,药代动力学,药效学及抗肿瘤活性。

Vanucizumab是一种尚处于研究阶段的抗血管生产药物,靶向VEGF-A和Ang-2.CLIN CANCER RES近期发表了一篇文章,报道了Vanucizumab治疗晚期实体肿瘤的安全性,药代动力学,药效学及抗肿瘤活性。

接受标准治疗后耐药的晚期实体肿瘤患者接受两周1次(3-30mg/kg)或每周(10-30)mg/kg静脉Vanucizumab治疗。最终共42例患者接受了治疗。19mg/kg两周1次组出现1例剂量限值毒性,致死性的肺出血。最常见的毒性反应为高血压,贫血和头痛。17例患出现治疗相关≥3级毒性反应。每周治疗组毒性反应高于两周治疗组。未达到Vanucizumab的最大耐受剂量。药代动力学结果表明半衰期为6-9天。所有患者血浆VEGF-A和Ang-2水平均下降。2例接受30mg/kg治疗的患者(肾癌和结肠癌)确定出现部分反应。10例患者无疾病进展≥6个月。推荐进行进一步研究 的剂量为两周2000mg(约为30mg/kg每两周)。

文章最后认为,每两周接受Vanucizumab治疗具有一定的安全性和耐受性,与接受VEGF-A和Ang/Tie2通路选择性抑制剂单药治疗相似。Vanucizumab会调节其肿瘤血管生成靶标,影响肿瘤血管生成,具有一定的抗肿瘤活性。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687711, encodeId=e0da168e71155, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Thu Aug 02 05:53:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911965, encodeId=fc9d19119656b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Apr 30 12:53:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754575, encodeId=881c1e5457599, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Thu Jun 07 19:53:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379155, encodeId=20df13e91559c, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Apr 18 05:53:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306355, encodeId=dca830635530, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Mon Apr 16 15:39:24 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1687711, encodeId=e0da168e71155, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Thu Aug 02 05:53:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911965, encodeId=fc9d19119656b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Apr 30 12:53:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754575, encodeId=881c1e5457599, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Thu Jun 07 19:53:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379155, encodeId=20df13e91559c, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Apr 18 05:53:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306355, encodeId=dca830635530, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Mon Apr 16 15:39:24 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-04-30 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1687711, encodeId=e0da168e71155, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Thu Aug 02 05:53:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911965, encodeId=fc9d19119656b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Apr 30 12:53:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754575, encodeId=881c1e5457599, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Thu Jun 07 19:53:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379155, encodeId=20df13e91559c, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Apr 18 05:53:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306355, encodeId=dca830635530, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Mon Apr 16 15:39:24 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1687711, encodeId=e0da168e71155, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Thu Aug 02 05:53:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911965, encodeId=fc9d19119656b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Apr 30 12:53:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754575, encodeId=881c1e5457599, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Thu Jun 07 19:53:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379155, encodeId=20df13e91559c, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Apr 18 05:53:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306355, encodeId=dca830635530, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Mon Apr 16 15:39:24 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-04-18 weiz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1687711, encodeId=e0da168e71155, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Thu Aug 02 05:53:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911965, encodeId=fc9d19119656b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Apr 30 12:53:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754575, encodeId=881c1e5457599, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Thu Jun 07 19:53:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379155, encodeId=20df13e91559c, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Apr 18 05:53:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306355, encodeId=dca830635530, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Mon Apr 16 15:39:24 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-04-16 happsf

    学习

    0

相关资讯

CLIN CANCER RES:M7824治疗晚期实体肿瘤

人们对PD-1/PD-L1靶向治疗的热情正逐渐降温,部分原因便是该疗法仅在一部分患者中证明有效。为了增加反应率,许多进行中的临床试验均在评估抗PD-1/PD-L1药物与其他免疫治疗方式结合的效果。但是这些结合方式均存在限制。M7824是一种双功能融合蛋白,由抗PD-L1单抗与TGFβ“trap”融合而成。CLIN CANCER RES近期发表了一篇文章,报道M7824治疗晚期实体肿瘤的效果。

CLIN CANCER RES:ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果

鞘氨醇激酶(SK1,SK2)通过调节有丝分裂及S1P影响肿瘤生长。ABC294640是第一种口服的SK2抑制剂。CLIN CANCER RES近期发表了一篇文章,报道了ABC294640治疗实体肿瘤的Ⅰ期临床试验结果。

CLIN CANCER RES:IDO1口服抑制剂治疗晚期实体肿瘤

IDO1催化色氨酸降解为NFK。IDO1在许多实体肿瘤中过表达,促使肿瘤逃逸机体免疫监视。CLIN CANCER RES近期发表了一篇文章,报道了IDO1选择性抑制剂epacadostat(INCB024360)Ⅰ期临床试验结果。